Susanne Markmann

The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use

W. Eiermann, Mahdi Rezai, Sherko Kümmel et al. · Annals of Oncology · 2012 · 146 citations · Full text

Medicine, Oncology, Breast Oncology +16

Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Radoslav Chekerov, Felix Hilpert, Sven� Mahner et al. · The Lancet Oncology · 2018 · 109 citations

Medicine, Oncology, Pharmacology +13

Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: A Randomized Multicenter Phase II Trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group

Jalid Sehouli, Dirk Stengel, Philipp Harter et al. · Journal of Clinical Oncology · 2010 · 103 citations · Full text

Medicine, Oncology, Pharmacology +17

Prognostic value of Ca 125 levels during primary therapy.

Susanne Markmann, Bernd Gerber, Volker Briese · PubMed · 2007 · 19 citations

Medicine, Oncology, Surgery +17

Adjuvant sequential chemoradiation therapy in high-risk endometrial cancer: results of a prospective, multicenter phase-II study of the NOGGO (North-Eastern German Society of Gynaecological Oncology)

Alexander Mustea, Dominique Koensgen, Antje Belau et al. · Cancer Chemotherapy and Pharmacology · 2013 · 16 citations

Medicine, Gynecology, Oncology +15